Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.45 - HK$34.86
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$98.13B
Enterprise ValueHK$39.54K
Total Cash (Recent Filing)HK$2.45B
Total Debt (Recent Filing)HK$6.95B
Price to Earnings (P/E)49.5
Beta1.89
Next Earnings
Oct 22, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend Yield0.69%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.95Price Target Upside36.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.25
Revenue Forecast (FY)HK$18.96B
Bulls Say, Bears Say
Bulls Say
End-to-End CRDMO PlatformAn integrated service offering can deepen customer relationships, support cross-selling across the drug lifecycle and capture more program value than a single-service provider, supporting durable demand and recurring project opportunities.
Sustained ProfitabilityThe company remains meaningfully profitable while extending a multi-year revenue growth trend. Positive earnings provide a foundation for continued investment in capacity, capabilities and customer programs despite slower recent growth.
Acceptable Balance Sheet BaseA substantial equity base and moderate TTM leverage provide financial support for ongoing operations and strategic investment. Although debt has risen, the balance sheet remains broadly manageable rather than structurally overleveraged.
Bears Say
Weak Cash ConversionLimited conversion of accounting earnings into cash reduces internally generated financial flexibility. Persistent reinvestment or working-capital needs could constrain debt reduction, capacity expansion and resilience during weaker demand.
Rising Debt BurdenThe substantial debt increase raises fixed financial obligations and reduces room to absorb project delays or industry softness. Higher leverage may also limit the company’s ability to fund growth internally while cash generation remains weak.
Slowing Growth And Margin PressureMaturing growth and reduced margin levels suggest less operating cushion than in earlier periods. Cost, pricing, mix or reinvestment pressure could limit earnings expansion unless demand and utilization improve across the platform.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$34.86 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$98.13B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Aug 20, 2026. The company reported HK$0.268 earnings per share for the quarter, missing the consensus estimate of HK$0.278 by -HK$0.01.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.23 which represents an annual dividend yield of 0.69%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.34.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.268 in its last earnings report, missing expectations of HK$0.278. Following the earnings report the stock price went up 7.697%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$32.95 (36.50% Upside)
HK$32.95 (36.50% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
0.69%
Trailing 12-Months
Asset Growth
24.60%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
3759 Stock 12 Month Forecast
Average Price Target
HK$32.95
▲(36.50% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―